Key Trends in US Biopharma/Medtech Investing
March 31, 2016
1:00 PM - 5:00 PM
Yale Club Manhattan, Trumbull Room
1:00-1:30 PM Lunch and Networking
1:30-1:40 PM Opening Remarks
DoHyun Cho, PhD
CEO and President, W Medical Strategy Group / Chairman, New York Health Forum
1:40-2:20 PM Session 1
"Biopharma/ Medtech Funding
Joe McMenamin, MD, JD, Executive Vice President, WMSG (Moderator)
Katya Hancock, Director, Strategic Partnerships, StartUp Health
Sean Drake, Managing Director, Stony Lonesome Group LLC
2:20-3:00 PM Session 2
"The Key Factors to Raising Capital: What Will Attract Investors”
Kimberly Ha, Senior Director, FTI Consulting (Moderator)
Norman Yun, Managing Director, H.C Wainwright & Co.
Vincent Liu, PhD, Managing Director, Chief US Representative, Fosun Pharma
3:00-3:20 PM Networking Break
3:20-3:40 PM Award Ceremony (Awardees: Joe McMenamin and Kimberly Ha)
3:40-4:30 PM Session 3
“New Breed of Contributors: Alternative Biopharma/ Medtech”
Tony Chen, CEO, Primevax Immuno-Oncology, Inc (Moderator)
Frank Borchetta, CEO & Co-Founder, Repairogen Corporation
Imran Babar, PhD, Senior Associate, OrbiMed LLC
Karen Carr, Regional Development Officer, Gateway for Cancer Research
4:30 PM Closing
Moderator: Joe McMenamin, MD, JD
EVP, W Medical Strategy Group
Joe McMenamin is the Chief Legal Officer of W Medical Strategy Group. His practice is primarily focused on prevention of personal injury and wrongful death claims arising from professional health services and products, especially those regulated by FDA. He also advises clients on managing risks related to telemedicine, corporate use of the Internet, social media, communications between life science companies and physicians, compliance with FDA regulations, and Medicare reimbursement. He provided the legal analysis informing Maheu, et al., “The Mental Health Professional and the New Technologies: A Handbook for Practice Today” (2005), the first text of its kind.
Director, Strategic Partnerships, StartUp Health
At StartUp Health, Katya Hancock focuses on a broad range of activities designed to help Healthcare Transformers build equity value including leading the StartUp Health Network Team, which is focused on developing relationships with customer and investor stakeholders, building strategic partnerships that unite entrepreneurs with key industry stakeholders (GE, Kaiser, Aurora Health Care, AARP, and others) and more. Prior to StartUp Health, Katya worked in the technology industry as a key team member at three financial tech start-ups, helping two of them grow to be acquired by Fortune 500 companies. Her experience includes corporate strategy, strategic partnerships and business development, product management, marketing, and capital raising.
Managing Director, Stony Lonesome Group LLC
Sean Drake is the Founder and Managing Partner of Stony Lonesome Group. Previously he was a Partner at Endeavor Capital Management where he was responsible for leading the fundraising efforts and was also an active deal partner sourcing several opportunities and playing an active role in working with portfolio companies. His primary areas of expertise are in Defense & Security as well as Financial Services & Alternative Investments.
Moderator: Kimberly Ha
Senior Director, FTI Consulting
Kimberly Ha is currently Senior Director at FTI Consulting, Strategic Communications. Her focus area is Capital Markets and Healthcare. She was previously Global Editor for BioPharm Insight, an independent business intelligence product launched by the Financial Times Group. Kimberly has been a panelist and moderator at major healthcare conferences and events.
Managing Director, H.C Wainwright & Co.
Norman Yun is a Managing Director at H.C. Wainwright & Co., LLC. Prior to joining H.C Wainwright, He held position at Brookline group, LLC for institutional sales & Investment Banking. He has twenty years of experience in investment banking, institutional research sales, and trading. He helped raise nearly $20 million in Series A rounds for two pre-clinical therapeutics companies. His attention to research, analysis, and other value-added services has contributed to long-lasting relationships with clients.
Vincent Liu, PhD
Managing Director, Chief US Representative, Fosun Pharma
Vincent Liu joined International Business Division of Shanghai Fosun Pharmaceutical Group in 2009 to lead the effort in executing Fosun Pharma’s investment and M&A strategies in the North America region. Upon joining the company, He has made significant contribution to implanting Fosun Pharma’s international strategies. His achievements including helping the company to raise a $500 million private equity fund from oversea and setting up two JVs with large US and Canadian companies in China. Currently, he is focused on helping Wanbang and Fosun Pharma to acquire more product and technology for the Chinese market. He received his Ph.D. degree in Molecular Biology in Drexel University and MBA degree from the University of Rochester.
Moderator: Tony Chen
CEO, PrimeVax Immuno-Oncology, Inc
Tony Chen is responsible for setting PrimeVax's strategic direction. He works closely with the PrimeVax Scientific Board of Advisors to ensure that all strategies are supported by robust science. His experience spans management and strategy consulting, clinical research services, and the US Department of Health and Human Services (HHS). Prior to leading PrimeVax, he built and managed various strategy and management consulting teams in the healthcare space.
CEO & Co-Founder, Repairogen Corporation
Frank Borchetta is a co-founder and President of Repairogen Corporation, where his responsibilities include overseeing product development and building industry and investor relationships. He has over a decade of experience in the healthcare industry. Prior to co-founding Repairogen, he worked as an attorney providing legal counsel to a range of pharmaceutical and biotechnology companies, including both startups and Fortune 500 companies. He has extensive experience in the areas of intellectual property, technology licensing, and product development. He looks forward to continuing the development of breakthrough skincare products at Repairogen.
Imran Babar, PhD
Senior Associate, OrbiMed LLC
Imran Babar is a Senior Associate on the Private Equity team. Prior to joining OrbiMed, he was a Biotechnology Associate at Cowen & Company, where he covered 20+ companies in the therapeutics space. He also serves as the V.P. of Scientific Affairs for Rare Genomics Institute, nonprofit biotech focused on helping rare disease patients. Imran Babar completed his Ph.D. in molecular biology at Yale University, where he researched microRNAs as both causes and treatments for cancers. While at Yale, he was a Howard Hughes Fellow, Harvey Fellow, and a fellow for the Lindau Nobel Laureate Meeting for young scholars. Prior to Yale, he completed his B.A. in Biology at Carleton College and conducted research at M.I.T. and N.I.H.
President, Inspire LLC, Regional Development Officer, Gateway for Cancer Research
Karen Carr has over 25 years’ experience developing and growing international organizations as an architect, non-profit executive and fundraising professional. Her leadership has grown small nonprofits into nationally recognized organizations. Her strengths lie in creating sustainable business solutions and strategic partnerships with corporations, foundations, civic organizations, federal and state agencies, nonprofit organizations, health systems, universities, and individuals. Karen has raised millions of dollars for multiple international organizations, managed global operations, and grow deeper interconnectivity with new and existing partnerships.